title: Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV.
abstract: OBJECTIVE
  Lower pill burden leads to improved antiretroviral therapy (ART) adherence among HIV patients. Simpler dosing regimens have not been widely explored in real-world populations. We retrospectively assessed ART adherence, all-cause hospitalisation risk and costs, and other healthcare utilisation and costs in Medicaid enrollees with HIV treated with ART as a once-daily single-tablet regimen (STR) or two or more pills per day (2+PPD).
  
  
  METHODS
  Patients with an HIV diagnosis from 2005 to 2009 receiving complete ART (ie, two nucleoside/nucleotide reverse transcriptase inhibitors plus a third agent) for ≥60 days as STR or 2+PPD were selected and followed until the first of (1) discontinuation of the complete ART, (2) loss of enrolment or (3) end of database. Adherence was measured using the medication possession ratio. Monthly all-cause healthcare utilisation and costs were observed from regimen initiation until follow-up end.
  
  
  RESULTS
  Of the 7381 patients who met inclusion criteria, 1797 were treated with STR and 5584 with 2+PPD. STR patients were significantly more likely to reach 95% adherence and had fewer hospitalisations than 2+PPD patients (both p<0.01). STR patients had mean (SD) total monthly costs of $2959 ($4962); 2+PPD patients had $3544 ($5811; p<0.001). Hospital costs accounted for 53.8% and pharmacy costs accounted for 32.5% of this difference. Multivariate analyses found that STR led to a 23% reduction in hospitalisations and a 17% reduction in overall healthcare costs. ART adherence appears to be a key mechanism mediating hospitalisation risk, as patients with ≥95% adherence (regardless of regimen type) had a lower hospitalisation rate compared with <95% adherence.
  
  
  CONCLUSIONS
  While it was expected that STR patients would have lower pharmacy costs, we also found that STR patients had fewer hospitalisations and lower hospital costs than 2+PPD patients, resulting in significantly lower total healthcare costs for STR patients.
authors.affiliation: CRI New England, Harvard Medical School, Boston, Massachusetts, USA.
authors.forename: Calvin J
authors.initials: CJ
authors.lastname: Cohen
authors.forename: Juliana L
authors.initials: JL
authors.lastname: Meyers
authors.forename: Keith L
authors.initials: KL
authors.lastname: Davis
keywords: Health Economics; Therapeutics
references.citation: HIV Clin Trials. 2011 Mar-Apr;12(2):71-8
references.pmid: 21498150
references.citation: PLoS One. 2012;7(2):e31591
references.pmid: 22384040
references.citation: AIDS Care. 2005 Nov;17(8):938-48
references.pmid: 16176890
references.citation: J Int Assoc Physicians AIDS Care (Chic). 2008 Sep-Oct;7(5):238-44
references.pmid: 18812590
references.citation: J Chronic Dis. 1987;40(5):373-83
references.pmid: 3558716
references.citation: Clin Infect Dis. 2001 Oct 15;33(8):1417-23
references.pmid: 11550118
references.citation: AIDS. 2001 Jun 15;15(9):1181-3
references.pmid: 11416722
references.citation: AIDS. 2010 Nov 27;24(18):2835-40
references.pmid: 21045636
references.citation: Ann Intern Med. 2003 Nov 18;139(10):810-6
references.pmid: 14623618
references.citation: AIDS. 2001 Jan 5;15(1):77-85
references.pmid: 11192871
references.citation: Clin Infect Dis. 2009 Feb 15;48(4):484-8
references.pmid: 19140758
references.citation: AIDS Patient Care STDS. 2010 Feb;24(2):87-96
references.pmid: 20156091
references.citation: Clin Infect Dis. 2006 Oct 1;43(7):939-41
references.pmid: 16941380
references.citation: J Acquir Immune Defic Syndr. 2001 Jun 1;27(2):143-52
references.pmid: 11404536
references.citation: Ann Intern Med. 2011 Apr 5;154(7):445-56
references.pmid: 21320923
references.citation: Am J Public Health. 2009 Jun;99(6):1045-9
references.pmid: 19372520
references.citation: Clin Infect Dis. 2011 Feb 15;52(4):493-506
references.pmid: 21245156
references.citation: Patient Prefer Adherence. 2010 May 13;4:115-25
references.pmid: 20517472
references.citation: Int J STD AIDS. 2004 Dec;15(12):803-10
references.pmid: 15601486
references.citation: N Engl J Med. 2006 Nov 30;355(22):2283-96
references.pmid: 17135583
references.citation: Pharmacoepidemiol Drug Saf. 2006 Aug;15(8):565-74; discussion 575-7
references.pmid: 16514590
references.citation: J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):163-74
references.pmid: 19357529
references.citation: JAMA. 2010 Jul 21;304(3):321-33
references.pmid: 20639566
references.citation: J Watch AIDS Clin Care. 2010 Apr;22(4):30
references.pmid: 20480928
references.citation: Pharmacoeconomics. 2010;28(1):23-34
references.pmid: 20014874
references.citation: Ann Intern Med. 2000 Jul 4;133(1):21-30
references.pmid: 10877736
references.citation: N Engl J Med. 2008 May 15;358(20):2095-106
references.pmid: 18480202
references.citation: Clin Infect Dis. 2011 Oct;53(8):807-16
references.pmid: 21921224